Buprenorphine: a “win-win” for acute postoperative pain
Publication Title: Buprenorphine: a “win-win” for acute postoperative pain
Summary
- Question
This letter-to-the-editor describes the benefits of using buprenorphine, a medication best known as a treatment for opioid use disorder (OUD), as a safer alternative to standard opioids for managing acute postoperative pain. The authors explored its effectiveness in reducing pain and minimizing the risks associated with opioid use, such as respiratory depression and addiction.
- Why it Matters
- Opioid use after surgery can lead to serious issues, including addiction (OUD) and overdose. Despite efforts to limit opioid exposure, surgical patients still face significant risks, with an estimated 358,000 cases of postoperative OUD and 13,410 overdoses annually in the U.S. Buprenorphine, which has unique properties such as lower risk of respiratory depression and reduced potential for misuse, may offer a safer option for pain management. Its use could address both the immediate need for effective pain relief and the long-term public health challenge of the opioid crisis.
- Methods
- The authors reviewed existing evidence, including clinical practice guidelines, retrospective studies, and meta-analyses, to assess buprenorphine's safety and effectiveness for acute pain management. They also examined its pharmacological properties and outcomes in surgical and emergency care settings. This was a narrative synthesis rather than a new clinical trial.
- Key Findings
Buprenorphine demonstrated multiple advantages over traditional opioids. It effectively reduced postoperative pain intensity and the need for additional pain medication. Unlike standard opioids, it posed a lower risk of respiratory depression—a leading cause of opioid-related deaths. Buprenorphine also showed less potential for misuse and addiction due to its milder euphoric effects, reduced withdrawal syndrome, and multimodal mechanisms of action, such as acting on multiple opioid receptors. Evidence from surgical and emergency care settings confirmed its feasibility and safety.
- Implications
- Buprenorphine could become a safer frontline option for managing both acute and chronic pain, potentially reducing the public health burden of opioid-related harms. Its ability to provide effective pain relief with fewer risks makes it a promising alternative in clinical practice. However, it should still be used cautiously within a multimodal pain management plan, emphasizing the lowest effective dose for the shortest duration.
- Next Steps
The authors emphasized the need for further studies to evaluate the long-term risks and benefits of buprenorphine for postoperative pain. Future research should focus on its impact on preventing OUD and overdose, as well as optimizing its use in various clinical settings.
- Funding Information
- The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or any of its academic affiliates. Yale University also provided funding and support for this research.
Full Citation
Authors
Thomas Hickey, MD, MS, FASA
First AuthorAssistant Professor
Eugene R Viscusi
Last Author